Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Similar articles for PubMed (Select 23775649)

1.

VII. Management of nodular lymphocyte-predominant Hodgkin lymphoma.

Eichenauer DA, Engert A.

Hematol Oncol. 2013 Jun;31 Suppl 1:47-50. doi: 10.1002/hon.2067. Review. No abstract available.

PMID:
23775649
2.

The unique entity of nodular lymphocyte-predominant Hodgkin lymphoma: current approaches to diagnosis and management.

Hawkes EA, Wotherspoon A, Cunningham D.

Leuk Lymphoma. 2012 Mar;53(3):354-61. doi: 10.3109/10428194.2011.608455. Epub 2011 Sep 19. Review.

PMID:
21812538
3.

Modern management of lymphocyte-predominant Hodgkin lymphoma.

Xing KH, Savage KJ.

Br J Haematol. 2013 May;161(3):316-29. doi: 10.1111/bjh.12244. Epub 2013 Feb 8. Review.

PMID:
23398605
4.

Treatment of lymphocyte-predominant Hodgkin lymphoma.

Engert A.

Ann Oncol. 2008 Jun;19 Suppl 4:iv45-6. doi: 10.1093/annonc/mdn194. Review. No abstract available.

5.

[Nodular lymphocyte-predominant Hodgkin lymphoma in children: clinical course, biology, and management].

Gorde-Grosjean S, Guimard G, Lambilliotte A, Coulomb-Lhermine A, Montravers F, Landman-Parker J.

Bull Cancer. 2014 Sep;101(9):881-90. doi: 10.1684/bdc.2014.2021. Review. French.

PMID:
25296072
6.

Hodgkin lymphoma.

Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Bello CM, Bierman PJ, Blum KA, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Weiss L, Winter JN, Yahalom J; NCCN Hodgkin Lymphoma.

J Natl Compr Canc Netw. 2011 Sep 1;9(9):1020-58. No abstract available.

PMID:
21917626
7.

Lymphocyte-predominant Hodgkin lymphoma--clinical features and treatment outcomes from a 30-year experience.

Jackson C, Sirohi B, Cunningham D, Horwich A, Thomas K, Wotherspoon A.

Ann Oncol. 2010 Oct;21(10):2061-8. doi: 10.1093/annonc/mdq063. Epub 2010 Mar 23.

8.

Treatment strategies for pediatric nodular lymphocyte predominant Hodgkin's lymphoma.

Vassilakopoulos TP, Angelopoulou MK, Pangalis GA.

Leuk Lymphoma. 2006 Aug;47(8):1450-1. No abstract available.

PMID:
16966251
9.

Nodular lymphocyte predominant hodgkin lymphoma: biology, diagnosis and treatment.

Goel A, Fan W, Patel AA, Devabhaktuni M, Grossbard ML.

Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):261-70. doi: 10.1016/j.clml.2014.01.006. Epub 2014 Feb 3. Review.

PMID:
24650975
10.

Nodular lymphocyte predominant Hodgkin lymphoma: diagnostic pearls and pitfalls.

Smith LB.

Arch Pathol Lab Med. 2010 Oct;134(10):1434-9. doi: 10.1043/2010-0207-OA.1.

PMID:
20923296
11.

Refractory Hodgkin lymphoma responds to pentostatin (2'-deoxycoformycin).

Braiteh F, Ng C, Kurzrock R.

Leuk Lymphoma. 2006 Feb;47(2):373-5. No abstract available.

PMID:
16321875
12.

Nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents--a comprehensive review of biology, clinical course and treatment options.

Shankar A, Daw S.

Br J Haematol. 2012 Nov;159(3):288-98. doi: 10.1111/bjh.12055. Epub 2012 Sep 21. Review.

PMID:
22994199
13.

Nodular lymphocyte predominant Hodgkin lymphoma in siblings.

Campbell GN, Lloyd J, Wotherspoon A, Coulter C, Bain BJ.

Leuk Lymphoma. 2004 Mar;45(3):609-11.

PMID:
15160926
14.

The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma.

Maeda LS, Advani RH.

Curr Opin Oncol. 2009 Sep;21(5):397-400. doi: 10.1097/CCO.0b013e32832f3ca3. Review.

PMID:
19606035
15.

Follicular peripheral T-cell lymphoma expands the spectrum of classical Hodgkin lymphoma mimics.

Moroch J, Copie-Bergman C, de Leval L, Plonquet A, Martin-Garcia N, Delfau-Larue MH, Molinier-Frenkel V, Belhadj K, Haioun C, Audouin J, Swerdlow SH, Marafioti T, Gaulard P.

Am J Surg Pathol. 2012 Nov;36(11):1636-46. doi: 10.1097/PAS.0b013e318268d9ff.

PMID:
23073322
16.

[Malignant lymphoma in pediatrics].

Ise T.

Rinsho Hoshasen. 1985 Oct;30(11):1415-25. Review. Japanese. No abstract available.

PMID:
3910879
17.

Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Engert A, Eichenauer DA, Dreyling M; ESMO Guidelines Working Group.

Ann Oncol. 2010 May;21 Suppl 5:v168-71. doi: 10.1093/annonc/mdq181. No abstract available.

18.

Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease.

Bodis S, Kraus MD, Pinkus G, Silver B, Kadin ME, Canellos GP, Shulman LN, Tarbell NJ, Mauch PM.

J Clin Oncol. 1997 Sep;15(9):3060-6.

PMID:
9294468
19.

European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes.

Anagnostopoulos I, Hansmann ML, Franssila K, Harris M, Harris NL, Jaffe ES, Han J, van Krieken JM, Poppema S, Marafioti T, Franklin J, Sextro M, Diehl V, Stein H.

Blood. 2000 Sep 1;96(5):1889-99.

20.

[Standard therapy and research questions in Hodgkin lymphoma].

Suzuki T.

Rinsho Ketsueki. 2012 Oct;53(10):1615-23. Review. Japanese. No abstract available.

PMID:
23037734
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk